Completed OBSERVATIONAL NCT02990117

ICS Treatment Compliance of Asthma Patients

An In-depth Understanding of Determinants of Inhaled ICS Treatment Compliance of Asthma Patients: Generate Data From Structured Patient Interview & Cross Sectional Survey

Sponsor: AstraZeneca

Conditions Asthma, Allergic

Interventions No Intervention

Updated 8 times since 2017 Last updated: Aug 12, 2019 Started: Nov 1, 2016 Primary completion: Jan 20, 2018 Completion: Jan 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02990117, this observational or N/A phase trial focuses on Asthma, Allergic and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Sep 2019 — Jan 2021 [monthly]

Completed

Status: Unknown Status → Completed
Jan 2019 — Sep 2019 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Jan 2019 [monthly]

Not Yet Recruiting
Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Not Yet Recruiting NA

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
First Affiliated Hospital Xi'an Jiaotong University

Data source: First Affiliated Hospital Xi'an Jiaotong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.